All In Biotech

Drug Trial Radar · NCT06892639

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

Evaluation of Dabocemagene Autoficel (D-Fi; FCX-007; Genetically Modified Autologous Human Dermal Fibroblasts) for the Treatment of Wounds Due to Dystropic Epidermolysis Bullosa

Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Mar 27, 2025

Primary completion

Sep 2027

Study completion Feb 2042

Sponsor

Lead sponsor
Castle Creek Biosciences, LLC.Industry
Sponsor type
Industry
Collaborators
Prosoft Clinical
First posted
Mar 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.

Conditions

  • Dystrophic Epidermolysis Bullosa

Interventions

  • D-FiBiological

    D-Fi is composed of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The difference in Complete (100%) Wound Closure of the Target Wound Pair at either Week 22 (Visit 6), and Week 24 (Visit 7) or at Week 24 (Visit 7) and Week 26 (Visit 8) as assessed by a Blinded Assessor.Time frame: Week 26

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University School of Medicine, Dermatology

    Redwood City, California

  • Mission Dermatology

    Santa Margarita, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • University of Massachusetts

    Worcester, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.